Understanding how certain proteins affect brain recovery after injury
Novel role and mechanisms of histone deacetylases in traumatic brain injury
This study is looking at how certain proteins in the brain can affect the way immune cells respond after a traumatic brain injury, with the goal of finding new treatments that help you recover better and feel less inflammation.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10665669 on NIH RePORTER |
What this research studies
This research investigates the role of histone deacetylases (HDACs) in the brain's response to traumatic brain injury (TBI). It focuses on how different types of HDACs can influence the behavior of immune cells in the brain, which can either worsen or help repair brain damage. By identifying the specific HDAC subtypes involved, the research aims to develop targeted therapies that enhance recovery while minimizing potential side effects. Patients may benefit from new treatments that improve neurological function and reduce inflammation after TBI.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have experienced a traumatic brain injury and are seeking innovative treatment options.
Not a fit: Patients with non-traumatic brain injuries or those who do not have a history of brain injury may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly improve recovery outcomes for patients with traumatic brain injuries.
How similar studies have performed: Previous studies have shown promise in using HDAC inhibitors to mitigate brain inflammation and improve neurological outcomes, suggesting a potential for success in this area of research.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Dixon, C Edward — University of Pittsburgh at Pittsburgh
- Study coordinator: Dixon, C Edward
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.